IAS 2011: HIV Prevention -- A Women's Revolution [VIDEO]
- Details
- Category: HIV Prevention
- Published on Tuesday, 26 July 2011 00:00
- Written by Video
The 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) held last week in Rome heralded remarkable data showing that early HIV treatment and pre-exposure prophylaxis (PrEP) can dramatically reduce the risk of HIV transmission.
But biomedical prevention methods will only work if people have access to them, and many women worldwide do not have access due to lack of economic resources or the right of self-determination.
IAS 2011: New NNRTI Lersivirine Looks Good in Phase 2 Study
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 21 July 2011 00:00
- Written by Liz Highleyman
Lersivirine, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), lowered HIV viral load about as well as efavirenz (Sustiva) for people starting antiretroviral therapy for the first time, researchers reported at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) this week in Rome. 
HIV Drug Development News from IAS 2011 [VIDEO]
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 20 July 2011 00:00
- Written by Gregory Fowler
Cal Cohen from the Community Research Institute of New England summarizes reports about experimental antiretroviral agents -- and new strategies for using existing drugs -- presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Rome. 
IAS 2011: Cognitive Impairment is Common, but ART Reduces Risk
- Details
- Category: Neurocognitive Problems
- Published on Wednesday, 20 July 2011 00:00
- Written by Liz Highleyman
Cognitive impairment remains common among people with HIV and is linked to more severe immune deficiency and absence of treatment, researchers reported at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) this week in Rome. But drugs that penetrate the central nervous system do not appear to improve overall outcomes. 
IAS 2011: Randomized Trial Supports Earlier Treatment
- Details
- Category: When to Start ART?
- Published on Wednesday, 20 July 2011 00:00
- Written by Paul Dalton
The large HPTN 052 trial, best known for showing that early antiretroviral treatment prevents HIV transmission, also found virological, immunological, and clinical benefit to starting HIV treatment sooner.
More Articles...
- IAS 2011: Once-daily Elvitegravir Matches Twice-daily Raltegravir
- IAS 2011: The Proof is Here: HIV Treatment is HIV Prevention
- IAS 2011: Coronary Artery Calcification Linked to Bone Loss
- IAS 2011: Stakeholders Call for HIV Cure Research
- IAS 2011: HIV Treatment as Prevention: HPTN 052 Offers Proof [VIDEO]
- IAS 2011: Changing Face of HIV Vaccine Research [VIDEO]
- IAS 2011: Transplants Safe for HIV+ People but HCV Adds Risk
- IAS 2011: Studies Confirm PrEP, Early ART Prevent HIV Transmission [VIDEO]
- IAS 2011: Universal Access to Science [VIDEO]
- IAS 2011: Biomedical Prevention a Watershed, Global Access Remains Elusive
Web Design and Development by